The Leu7Pro polymorphism of neuropeptide Y is associated with younger age of onset of type 2 diabetes mellitus and increased risk for nephropathy in subjects with diabetic retinopathy

Experimental and Clinical Endocrinology and Diabetes

Volumn 114, Issue 4, 2006, Pages 147-152

  Jaakkola, Ulriikka ^a,b   Pesonen, U ^a   Vainio Jylha E ^c   Koulu, M ^a   Pollonen M ^c   Kallio, J ^a  

^a UNIVERSITY OF TURKU   (Finland)

^b TURKU CITY HOSPITAL   (Finland)

^c TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Diabetic complications; NPY polymorphism; Onset of diabetes

Indexed keywords

LEUCINE; NEUROPEPTIDE Y; PROLINE;

ADULT; AGED; ARTICLE; CAUCASIAN; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DISEASE COURSE; DISEASE SEVERITY; DNA POLYMORPHISM; FEMALE; GENETIC ASSOCIATION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ONSET AGE; PRIORITY JOURNAL; PROTEINURIA;

ADULT; AGE FACTORS; AGED; AMINO ACID SUBSTITUTION; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DIABETIC RETINOPATHY; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROPEPTIDE Y; POLYMORPHISM, GENETIC; PREDICTIVE VALUE OF TESTS; PROTEIN PRECURSORS; PROTEINURIA; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 33744929367     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-924079     Document Type: Article

References (28)

1. Awata T, Inoue K, Kurihara S, Ohkubo T, Watanabe M, Inukai K, Inoue I, Katayama S. A common polymorphism in the 5′-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes. Diabetes 2002; 51: 1635-1639
2. Bennet WM, Wang ZL, Jones PM, Wang RM, James RF, London NJ, Ghatei MA, Bloom SR. Presence of neuropeptide Y and its messenger ribonucleic acid in human islets: evidence for a possible paracrine role. J Clin Endocrinol Metab 1996; 81: 2117-2120
3. Birinci A, Birinci H, Abidinoglu R, Durupinar B, Oge I. Diabetic retinopathy and HLA antigens in type 2 diabetes mellitus. Eur J Ophthalmol 2002; 12: 89-93
4. Ding B. Distribution of the NPY 1128C allele frequency in different populations. J Neural Transm 2003; 110: 1199-1204
5. El-Asrar AM, Al-Rubeaan KA, Al-Amro SA, Moharram OA, Kangave D. Retinopathy as a predictor of other diabetic complications. Int Ophthalmol 2001; 24: 1-11
6. Ferrannini E, Nannipieri M, Williams K, Gonzales C, Haffner SM, Stern MP. Mode of onset of type 2 diabetes from normal or impaired glucose tolerance. Diabetes 2004; 53: 160-165
7. Harris MI, Klein R, Welborn TA, Knuiman MW. Onset of NlDDM occurs at least 4-7yr before clinical diagnosis. Diabetes Care 1992; 15: 815-819
8. Jaakkola U, Kuusela T, Jartti T, Pesonen U, Koulu M, Vahlberg T, Kallio J. The Leu7Pro polymorphism of preproNPY is associated with decreased insulin secretion, delayed ghrelin suppression and increased cardiovascular responsiveness to norepinephrine during oral glucose-tolerance test. J Clin Endocrinol Metab 2005; 90: 3646-3652
9. Kallio J, Pesonen U, Jaakkola U, Karvonen MK, Helenius H, Koulu M. Changes in diurnal sympathoadrenal balance and pituitary hormone secretion in subjects with Leu7Pro polymorphism in the prepro-neuropeptide Y. J Clin Endocrinol Metab 2003; 88: 3278-3283
10. Kallio J, Pesonen U, Kaipio K, Karvonen MK, Jaakkola U, Heinonen OJ, Uusitupa MI, Koulu M. Altered intracellular processing and release of neuropeptide Y due to leucine 7 to proline 7 polymorphism in the signal peptide of preproneuropeptide Y in humans. FASEB J 2001a; 15: 1242-1244
11. Kallio J, Pesonen U, Karvonen MK, Kojima M, Hosoda H, Kangawa K, Koulu M. Enhanced exercise-induced GH secretion in subjects with Pro7 substitution in the prepro-NPY. J Clin Endocrinol Metab 2001b; 86: 5348-5352
12. Karvonen MK, Valkonen VP, Lakka TA, Salonen R, Koulu M, Pesonen U, Tuomainen TP, Kauhanen J, Nyyssonen K, Lakka HM, Uusitupa MI, Salonen JT. Leucine7 to proline7 polymorphism in the preproneuropeptide Y is associated with the progression of carotid atherosclerosis, blood pressure and serum lipids in Finnish men. Atherosclerosis 2001; 159: 145-151
13. Karvonen MK, Pesonen U, Koulu M, Niskanen L, Laakso M, Rissanen A, Dekker JM, Hart LM, Valve R, Uusitupa MI. Association of a leucine(7)-to-proline(7) polymorphism in the signal peptide of neuropeptide Y with high serum cholesterol and LDL cholesterol levels. Nat Med 1998; 4: 1434-1437
14. Koulu M, Movafagh S, Tuohimaa J, Jaakkola U, Kallio J, Pesonen U. Geng Y, Karvonen MK, Vainio-Jylha E, Pollonen M, Kaipio-Salmi K, Seppala H, Lee EW, Higgins RD, Zukowska Z. Neuropeptide Y and Y2-receptor are involved in development of diabetic retinopathy and retinal neovascularization. Ann Med 2004; 36: 232-240
15. Kumaramanickavel G, Sripriya S, Vellanki RN, Upadyay NK, Badrinath SS, Arokiasamy T, Sukumar B, Vidhya A, Joseph B, Sharma T, Gopal L. Tumor necrosis factor allelic polymorphism with diabetic retinopathy in India. Diabetes Res Clin Pract 2001; 54: 89-94
16. Lee EW, Michalkiewicz M, Kitlinska J, Kalezic I, Switalska H, Yoo P. Sangkharat A, Ji H, Li L, Michalkiewicz T, Ljubisavljevic M, Johansson H, Grant DS, Zukowska Z. Neuropeptide Y induces ischemic angiogenesis and restores function of ischemic skeletal muscles. J Clin Invest 2003; 111: 1853-1862
17. Neugebauer S, Baba T, Watanabe T. Association of the nitric oxide synthase gene polymorphism with an increased risk for progression to diabetic nephropathy in type 2 diabetes. Diabetes 2000; 49: 500-503
18. Niskanen L, Karvonen MK, Valve R, Koulu M, Pesonen U, Mercuri M, Rauramaa R, Toyry J, Laakso M, Uusitupa MI. Leucine 7 to proline 7 polymorphism in the neuropeptide Y gene is associated with enhanced carotid atherosclerosis in elderly patients with type 2 diabetes and control subjects. J Clin Endocrinol Metab 2000a; 85: 2266-2269
19. Niskanen L, Voutilainen-Kaunisto R, Terasvirta M, Karvonen MK, Valve R, Pesonen U, Laakso M, Uusitupa MI, Koulu M. Leucine 7 to proline 7 polymorphism in the neuropeptide y gene is associated with retinopathy in type 2 diabetes. Exp Clin Endocrinol Diabetes 2000b; 108: 235-236
20. Nordman S, Ding B, Ostenson CG, Karvestedt L, Brismar K, Efendic S, Gu HF. Leu7Pro polymorphism in the neuropeptide Y (NPY) gene is associated with impaired glucose tolerance and type 2 diabetes in Swedish men. Exp Clin Endocrinol Diabetes 2005; 113: 282-287
21. Olmos P, Futers S, Acosta AM, Siegel S, Maiz A, Schiaffino R, Morales P, Diaz R, Arriagada P, Claro JC, Vega R, Vollrath V, Velasco S, Emmerich M. (AC)23 [Z-2] polymorphism of the aldose reductase gene and fast progression of retinopathy in Chilean type 2 diabetics. Diabetes Res Clin Pract 2000; 47: 169-176
22. Pedrazzini T, Pralong F, Grouzmann E. Neuropeptide Y: the universal soldier. Cell Mol Life Sci 2003; 60: 350-377
23. Pettersson-Fernholm K, Karvonen MK, Kallio J, Forsblom CM, Koulu M, Pesonen U, Fagerudd JA, Groop PH, FinnDiane Study Group. Leucine 7 to proline 7 polymorphism in the preproneuropeptide Y is associated with proteinuria, coronary heart disease, and glycemic control in type 1 diabetic patients. Diabetes Care 2004; 27: 503-509
24. Pihlajamaki J, Karhapaa P, Vauhkonen I, Kekalainen P, Kareinen A, Viitanen L, Pesonen U, Kallio J, Uusitupa M, Laakso M. The Leu7Pro polymorphism of the neuropeptide Y gene regulates free fatty acid metabolism. Metabolism 2003; 52: 643-646
25. Ray D, Mishra M, Ralph S, Read I, Davies R, Brenchley P. Association of the VEGF gene with proliferative diabetic retinopathy but not proteinuria in diabetes. Diabetes 2004; 53: 861-864
26. Rohner-Jeanrenaud F. Neuroendocrine regulation of nutrient partitioning. Ann N Y Acad Sci 1999; 892: 261-271
27. Satoh C, Satoh F, Takahashi K, Murakami O, Sone M, Totsune K, Yabe T, Ohneda M, Fukuda M, Sugimura K, Ogawa S, Nagakubo H, Sato T, Mouri T. Elevated plasma immunoreactive neuropeptide Y concentrations and its increased urinary excretion in patients with advanced diabetic nephropathy. Endocr J 1999; 46: 139-146
28. Taverna MJ, Sola A, Guyot-Argenton C, Pacher N, Bruzzo F, Chevalier A, Slama G, Reach G, Selam JL. eNOS4 polymorphism of the endothelial nitric oxide synthase predicts risk for severe diabetic retinopathy. Diabet Med 2002; 19: 240-245